Barclays
PAVM icon

Barclays’s PAVmed PAVM Stock Holding History

Barclays’s Portfolio PAVM Stock Details PAVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-75
Closed -$446 – 5640
2026
Q2 		$446 Buy
+75
New +$531 ﹤0.01% 5024
2025
Q4 		– Sell
-2
Closed -$29 – 5560
2025
Q3 		$29 Buy
+2
New +$30 ﹤0.01% 5343
2023
Q1 		– Sell
-18
Closed -$3.84K – 5284
2022
Q4 		$3.84K Hold
18
– – ﹤0.01% 5036
2022
Q3 		$7K Hold
18
– – ﹤0.01% 4423
2022
Q2 		$7K Sell
18
-26
-59% -$12.6K ﹤0.01% 4721
2022
Q1 		$27K Sell
44
-170
-79% -$126K ﹤0.01% 4341
2021
Q4 		$237K Buy
214
+106
+98% +$230K ﹤0.01% 3503
2021
Q3 		$415K Buy
108
+61
+130% +$192K ﹤0.01% 3281
2021
Q2 		$137K Sell
47
-69
-59% -$163K ﹤0.01% 3717
2021
Q1 		$232K Buy
116
+89
+330% +$134K ﹤0.01% 3638
2020
Q4 		$26K Sell
27
-10
-27% -$8.55K ﹤0.01% 4625
2020
Q3 		$29K Sell
37
-7
-16% -$6.23K ﹤0.01% 4818
2020
Q2 		$42K Buy
+44
New +$44K ﹤0.01% 5003
2020
Q1 		– Hold
0
– – – 6381
2019
Q4 		– Hold
0
– – – 6692

Other funds holding PAVM

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Parkside Financial Bank & Trust
Parkside Financial Bank & Trust Saint Louis, Missouri $1.51B AUM 17.86% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Foresight Capital Management Advisors
Foresight Capital Management Advisors Saline, Michigan $202M AUM 20.26% 1-Year Est. Return

Barclays's PAVM Position: Q3 2026 in Review

Barclays sold out of PAVmed (PAVM) in Q3 2026, closing a stake of 75 shares — an estimated $446 sold.

Barclays first reported a position in PAVM in Q2 2020 and held it in 13 quarters. The position peaked at $415K in Q3 2021. 8 funds tracked by Wall St. Rank hold PAVM as of Q3 2026.

  • Barclays reported no remaining PAVmed position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 75 PAVmed shares in Q3 2026, an estimated $446.
  • Barclays first reported a position in PAVmed in Q2 2020 and held it in 13 quarters.
  • Barclays's PAVmed position peaked at $415K in Q3 2021.
  • 8 funds tracked by Wall St. Rank held PAVmed as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.